Congress Should Fix FDA Neglected Disease Drug Voucher Program’s Flaws

PLOS “Speaking of Medicine”: FDA Voucher for Leishmaniasis Treatment: Can Both Patients and Companies Win?
Bernard Pécoul, executive director of the Drugs for Neglected Diseases initiative (DNDi), and Manica Balasegaram, executive director of the MSF Access Campaign, discuss how flaws in the FDA Priority Review Voucher (PRV) program have rewarded companies without consideration to patient access to treatments for neglected diseases and they call on Congress to “fix the PRV so that it truly incentivizes R&D, and does not simply reward the registration of an existing drug” (1/20).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.